Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Cbd wellness center hesperia valley

Diabetic Cannabis-derived CBD Nephropathy treating in



  • Diabetic Cannabis-derived CBD Nephropathy treating in
  • How a Tiny Island Nation Could Use Cannabis to Disrupt Diabetes Care
  • What is CBD?
  • THC treatment reduced the development of atherosclerotic the plant-derived cannabinoid CBD attenuates inflammation, oxidative Diabetic Nephropathy. However, treatment options for diabetic retinopathy are limited and display poor efficacy These include cannabidiol (CBD) that activates, in preclinical models, . The marijuana-derived cannabinoids (−)-Δ9–tetrahydrocannabinol (THC) and . The prevalence of diabetic peripheral neuropathy (DPN) appears to be increasing approved medications for the treatment of diabetic peripheral neuropathy. . The items of the BDI were clinically derived and have undergone .. Since the CBD concentration in the cannabis used in this study was so low.

    Diabetic Cannabis-derived CBD Nephropathy treating in

    People who are more likely to be diagnosed with diabetes — specifically type two diabetes — often have insulin resistance and high fasting insulin levels. They also have low levels of high-density lipoprotein cholesterol. These people also had higher levels of high-density lipoprotein cholesterol, as well as insulin resistance levels that were 17 percent lower than those who had never used cannabis.

    People who had previously used cannabis or hemp but were not current users also had better fasting insulin, cholesterol, and insulin resistance levels compared to those who had never used it. But, their results were not as good as those of current users. When the cells reject insulin, they cannot absorb glucose sugar , which is needed for energy.

    This causes glucose to build up in the bloodstream and lead to high blood sugar levels. When inflammation is reduced, the immune system and cardiovascular system function better. A lack of inflammation can also improve cell growth and improve sugar metabolism. If all of these systems throughout the body are working as efficiently as possible, the chances of developing insulin resistance and diabetes are decreased.

    Research shows that cannabis and hemp use has been linked to a smaller waist circumference, a lower BMI body mass index and decreased obesity levels. CBD performs several different functions in the body that contribute to its weight management benefits. In addition to helping users get rid of extra weight in the form of inflammation, it may also act as an appetite suppressant. During this process, white adipose is converted to brown adipose.

    For people who currently struggle with diabetes, neuropathy, or nerve damage, is a common occurrence. Most diabetics experience neuropathy in the hands and feet, but any organ can be affected.

    Common symptoms of diabetic neuropathy include pain, numbness, and tingling in the affected area. Studies suggest that CBD appears to work better than conventional medicine when it comes to treating diabetic neuropathy. CBD may also protect the liver from oxidative stress, which seems to contribute to the development of neuropathy. In addition to neuropathy, many diabetics also struggle with chronic skin sensitivity and irritation. CBD may help heal these skin conditions and provide diabetics relief from the itching, burning, and general discomfort that accompanies them.

    Studies suggest that CBD has anti-aging properties, too, that may be beneficial for healing and preventing painful skin conditions. CBD oil can be used for skin irritation. Many people report that CBD-infused lotions and creams are also highly effective for those who want a more targeted treatment method. CBD oil can help you feel like a better version of yourself. We offer free shipping on all orders!

    Want it there faster? We also offer a wide range of shipping upgrades. Additional 8 subjects were excluded for other reasons, resulting in 16 consenting participants that were randomized. One participant completed only 2 treatments [placebo and high dose]; those data were used in analyses as appropriate.

    Baseline characteristics of the study's cohort are given in Table 1. In general, the sample consisted of approximately equal numbers of men and women, of African-American or White ethnicity, who were middle-aged or older, and who had longstanding, often insulin-requiring, diabetes mellitus. Patients reported chronic neuropathic pain of moderately severe intensity.

    One third of the group had a BMI in the obese range. Users of analgesic medications were on average 3. Mixed effects model shows that, with every 1 log 10 units of time, spontaneous pain intensity score decreased, on average, by 1. Specifically, average pain intensity score in the placebo dose was 0. On the dose level, only the differences in pain scores between high dose and other doses remained significant.

    Specifically, the adjusted mean pain scores for high dose were 1. For evoked foam brush pain the average reduction in pain was 0. Similarly, for evoked von Frey pain the average reduction in pain was 0. These differences remained significant, after adjusting for prior treatment [placebo vs high: Mean change in pain intensity scores was compared between conditions at every time point. Table 2 lists estimated means and standard deviations of change in pain adjusted for baseline pain values, where negative values indicate decrease in pain as compared to baseline.

    The minimum pain score achieved during each 4-hour session was obtained for every participant, as well as the time in minutes it took to achieve it.

    The unadjusted average values for these measures are given in Table 3 , separately for each dose and pain type. On average, the lowest minimum pain score was achieved in the high dose and the highest minimum pain score was in the placebo dose. There were no statistical differences between doses in average time it took to reach the lowest pain score. Lower times to minimum pain indicate faster pain relief.

    Analyses of percebt reduction in foam brush evoked and, separately, von Frey evoked pain scores did not show statistically significant differences between doses. Results for the neurocognitive testing scaled scores at each time point are shown in Figures 2A-C.

    The overall tests for differences between doses in mean changes from baseline at each time point were not significant for any of the cognitive tests. There were no significant differences between treatment conditions on Trail Making Part A at any time point. Given the small sample size and limited power, we also examined effect sizes.

    Effect sizes were greater than 0. Analyses of changes in Subjective Highness Score showed a stair-step effect of dose that mostly wore off after 4 hours [ Table 4 ].

    Additionally, mixed effects models were used to correlate Subjective Highness Score with spontaneous pain score. The analysis estimated that, as Highness Score increased by 1 point, the pain score decreased on average by 0. Adverse effects of cannabis were defined as experiences of euphoria and somnolence [ Table 5 ]. Our short-term, single session, crossover study in general found a dose dependent reduction in pain intensity in response to inhaled cannabis in patients with DPN.

    Overall, our finding of an analgesic effect of cannabis is consistent with other trials of cannabis in diverse neuropathic pain syndromes. Nevertheless, there is some uncertainty regarding the dosing range that results in analgesia after administration of cannabis. Some recent studies on the potential effectiveness of cannabis have shown that a medium dose [3. This translated into a daily dose ranging from approximately 2mg to 7mg THC.

    Only the high dose separated from placebo. Studies in experimentally-induced pain suggest that high doses may increase pain.

    Cannabidiol [CBD] combination was only effective at the low and medium dose but not the high dose. There was a significant dose dependent effect of cannabis on both spontaneous and evoked pain in our study.

    However, the effect on spontaneous pain was more consistent than the effect on evoked pain. A previous study we performed in healthy volunteers using the same doses as those used in our current study showed a significant reduction in capsaicin-induced spontaneous and evoked pain but not secondary hyperalgesia. Marijuana contains nearly known compounds, of which over 80 are classified as cannabinoids.

    CBD is the second most abundant compound in the plant. A preliminary study in cancer patients showed that the THC: With respect to cognition, there were modest effects of treatment. Interestingly, the effect on speeded set switching was greatest at minutes, with the high dose vs. Of note, most of the scaled score differences were less than 1. However, it is possible that these changes could impact tasks requiring intact attention and speeded processing [e. This may limit the clinical usefulness with some patients.

    However, whether repeated dosing at low, clinically-effective levels results in increased tolerance to the psychoactive effects is not known and is an area in need of future research.. In addition, this study utilized a very brief battery, and thus did not address cognitive functions such as learning and memory, or psychomotor speed [e. Our study used vaporization of the cannabis leaf as the delivery method. Heating the cannabis leaves to below combustion temperatures [ degrees C] releases the cannabinoids in a vapor that is easily inhaled and titrated to effect.

    Vaporization is an attractive delivery method for research since it permits the inhalation of volatilized gases without exposure to hazardous pyrroles and the high concentrations of carbon monoxide than occurs with combustion. As shown in figure 1 , there is an initial steep drop in pain within the first 15 minutes followed by a slower decrease in pain over time.

    By comparison ingestion of cannabinoids results in a delayed and highly variable onset and offset of action across individuals, a reduced ability to titrate dosing, and more side effects. On the other hand, in clinical settings many individuals may find vaporization to be inconvenient or adverse in its own right. This may further limit the clinical applicability of cannabis. Finally all patients reported either euphoria or somnolence as adverse effects, which may limit the acceptability of cannabis for analgesia, as is the case for many patients who are prescribed opioids for pain relief.

    In any event this was a single dose study and no conclusions can be drawn over the long term tolerability as compared with currently available therapeutics dosed over weeks. Limitations of our study include possible lack of blinding due to the psychoactive effects of THC and cross-over design, the brief duration of the trial, a restricted assessment of neuropsychiatric and other adverse effects, and the small number of subjects in the study.

    There are two cross-over trials of cannabis that assessed blinding. However with continued exposure, the chance of guessing correctly increases. Another limitation is the small number of subjects in the study.

    Power analysis showed that we would need a total of 20 subjects to detect an effect, however the study was discontinued at 16 subjects due to difficulties with recruitment during the time-frame of funding. We chose to focus on anticipated AEs subjective highness, euphoria, somnolence and cognitive impairment and relied on the subjects to voluntarily report other AEs. Therefore, we may have missed more AEs than reported.

    In addition, we used the Michigan Neuropathy Screening Instrument. Although this instrument is a validated screening tool, the requirement for either reduced DTRs or abnormal electrophysiological abnormalities will push the selection of patients with at least a component of large fiber neuropathy, essentially excluding those with predominant small fiber neuropathy.

    Furthermore, there may have been an indirect effect on pain through a reduction in anxiety that results from cannabis. Despite these limitations, these preliminary findings, along with prior studies, suggest that cannabis might have analgesic effects in neuropathic pain syndromes, including in patients with treatment-refractory DPN.

    Larger randomized trials with longer-term follow-up are warranted to assess the analgesic effectiveness of cannabis. This small, short-term, placebo-controlled trial of inhaled cannabis demonstrated a dose dependent reduction in diabetic peripheral neuropathy pain in patients with treatment-refractory pain. This adds preliminary evidence to support further research on the efficacy of the cannabinoids in neuropathic pain. None of the authors have conflict of interests to report.

    National Center for Biotechnology Information , U. Author manuscript; available in PMC Dec Wallace , MD, 1 Thomas D. Atkinson , MD 3, 2. Author information Copyright and License information Disclaimer. The publisher's final edited version of this article is available at J Pain.

    See other articles in PMC that cite the published article. Abstract A randomized, double-blinded, placebo controlled crossover study was conducted in 16 patients with painful diabetic peripheral neuropathy to assess the short-term efficacy and tolerability of inhaled cannabis. METHODS A randomized, double-blinded, placebo controlled crossover study was conducted in sixteen patients with painful diabetic peripheral neuropathy to assess the short-term efficacy and tolerability of inhaled cannabis.

    Open in a separate window. Footnotes None of the authors have conflict of interests to report IND: Impact of Painful Diabetic Polyneuropathy on Patients. Lawson EF, Backonja M, editors. A Comprehensive Guide for Clinicians.

    Springer Science; New York: Boulton AJ, et al. Dyck PJ, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: Diabetes Res Clin Pract.

    Gordois A, et al. The health care costs of diabetic peripheral neuropathy in the US. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost.

    Dworkin RH, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. Recommendations for the pharmacological management of neuropathic pain: Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. Tsou K, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.

    Herkenham M, et al. Characterization and localization of cannabinoid receptors in rat brain. A quantitative in vitro autoradiographic study. Martin WJ, et al. An examination of the central sites of action of cannabinoid- induced antinociception in the rat. Marsicano G, Lutz B. Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Lim G, et al. Upregulation of spinal cannabinoidreceptors following nerve injury enhances the effects of Win 55, on neuropathic pain behaviors in rats.

    Siegling A, et al. Cannabinoid CB 1 receptor upregulation in a rat model of chronic neuropathic pain. Zhang J, et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.

    Dogrul A, et al. Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Ulugol A, et al. The effect of WIN 55,, a cannabinoid agonist, on tactile allodynia in diabetic rats. The synthetic cannabinoid WIN55, attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. J Pharmacol Exp Ther. Abrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy: Ellis RJ, et al.

    Smoked medicinal cannabis for neuropathic pain in HIV: Ware MA, et al. Smoked cannabis for chronic neuropathic pain: Wilsey B, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. Wiley Classics Library Edition. The Design and Analysis of Clinical Experiments.

    How a Tiny Island Nation Could Use Cannabis to Disrupt Diabetes Care

    Cannabis-Derived Agent May Offer Type 2 Diabetes Benefit (CBD) and Δ9- tetrahydrocannabivarin (THCV), the former derived from the cannabis plant A total 62 subjects with non–insulin-treated type 2 diabetes were randomized to one of Inhaled Cannabis Promising for Painful Diabetic Neuropathy. Cannabis-derived CBD in treating Diabetic Nephropathy. Diabetes is a leading cause of renal failure, accounting for 44% of all new cases in Medical Cannabis for Peripheral Neuropathy Treatment- Part 3 of 5 The amounts of THC or CBD, as well as the numerous secondary.

    What is CBD?



    Cannabis-Derived Agent May Offer Type 2 Diabetes Benefit (CBD) and Δ9- tetrahydrocannabivarin (THCV), the former derived from the cannabis plant A total 62 subjects with non–insulin-treated type 2 diabetes were randomized to one of Inhaled Cannabis Promising for Painful Diabetic Neuropathy.


    Cannabis-derived CBD in treating Diabetic Nephropathy. Diabetes is a leading cause of renal failure, accounting for 44% of all new cases in


    Medical Cannabis for Peripheral Neuropathy Treatment- Part 3 of 5 The amounts of THC or CBD, as well as the numerous secondary.


    OnTrack Diabetes investigates claims that cannabis can be “CBD is showing promise as a pain-reliever, an epilepsy treatment, and It may also ease the pain of peripheral neuropathy, she says. Unlike marijuana, the compound cannabidiol won't get you high even though it's derived from cannabis.


    Check out these facts about CBD and diabetes to see how this plant can help. The results of a five-year study showed that people who used cannabis or hemp on a medicine when it comes to treating diabetic neuropathy.

    Add Comment